stockportfolio.pro
XOMA Royalty Corporation (XOMA)
Healthcare · Biotechnology · NasdaqGM
XOMA Royalty Corporation revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.56M | $52.69M | $5.30M | $18.37M | $29.39M | $38.16M | $6.03M | $4.76M | $10.22M | $11.66M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-53.53M | $14.60M | $-13.34M | $-1.98M | $13.30M | $15.80M | $-17.10M | $-40.83M | $-13.82M | $31.71M |
| Net margin | -962.1% | 27.7% | -251.8% | -10.8% | 45.3% | 41.4% | -283.8% | -858.2% | -135.2% | 272.0% |
Source: XOMA Royalty Corporation SEC filings (10-K). 17 years of history available in the interactive view.
Explore 17 years of XOMA Royalty Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track XOMA in your portfolio →
XOMA Royalty Corporation financial history by metric
About XOMA Royalty Corporation
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
XOMA Royalty Corporation — frequently asked questions
What is XOMA Royalty Corporation's revenue?
XOMA Royalty Corporation (XOMA) reported revenue of $11.66M for fiscal year 2025, up 14.1% from the prior year, according to its SEC filings.
Is XOMA Royalty Corporation profitable?
Yes. XOMA earned net income of $31.71M in fiscal 2025, a net margin of 272.0%.
What is XOMA's P/E ratio?
XOMA Royalty Corporation trades at a price-to-earnings ratio of about 26.6 based on the latest data in our nightly-refreshed cache.
How fast is XOMA Royalty Corporation growing?
XOMA's revenue grew at roughly -16.9% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does XOMA Royalty Corporation have?
As of fiscal year 2025, XOMA carried roughly $108.98M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is XOMA Royalty Corporation's market cap?
XOMA Royalty Corporation (XOMA) has a market capitalization of about $524.31M, based on the latest data in our nightly-refreshed cache.
When does XOMA Royalty Corporation's fiscal year end?
XOMA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from XOMA Royalty Corporation's official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.